KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Capital Employed (2016 - 2025)

Nektar Therapeutics (NKTR) has 15 years of Return on Capital Employed data on record, last reported at 0.1% in Q3 2025.

  • For Q3 2025, Return on Capital Employed fell 30.0% year-over-year to 0.1%; the TTM value through Sep 2025 reached 0.1%, down 30.0%, while the annual FY2024 figure was 0.09%, 3.0% up from the prior year.
  • Return on Capital Employed reached 0.1% in Q3 2025 per NKTR's latest filing, up from 0.13% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.2% in Q3 2024 and bottomed at 0.37% in Q3 2021.
  • Average Return on Capital Employed over 5 years is 0.1%, with a median of 0.12% recorded in 2022.
  • Peak YoY movement for Return on Capital Employed: grew 28bps in 2024, then fell -30bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.1% in 2021, then decreased by -14bps to 0.11% in 2022, then plummeted by -39bps to 0.16% in 2023, then skyrocketed by 35bps to 0.1% in 2024, then rose by 7bps to 0.1% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.1% in Q3 2025, 0.13% in Q2 2025, and 0.16% in Q1 2025.